Core Viewpoint - Spero Therapeutics, Inc. (SPRO) is experiencing a downtrend with a 9.3% decline over the past four weeks, but it is in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - SPRO's current RSI reading is 27.37, suggesting that the heavy selling pressure may be exhausting, indicating a possible price rebound [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding SPRO, with a 6.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6] - SPRO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7]

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -18.52%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.33, delivering a surprise of 5.71%.Over the last four quarters, the company ...

Financial Position - Estimated cash and cash equivalents of approximately $76.3 million as of September 30, 2024[2] - Existing cash and cash equivalents expected to fund operating expenses and capital expenditures into mid-2026[5] Workforce and Restructuring - Company announced a workforce reduction of approximately 39% to refocus on strategic priorities around tebipenem HBr and R&D efforts[4] - Estimated restructuring charges of approximately $1.1 million related to severance pay and termination benefits[5] - Company may incur additional costs related to the workforce reduction not currently contemplated[5] Business Operations and Strategy - Company released an investor presentation providing updates on business and operations[6] - Company emphasizes reliance on third parties for manufacturing and commercialization of product candidates[11] Forward-Looking Statements - Forward-looking statements indicate potential regulatory delays and the need for additional funding[9] - Anticipated expenses and cash runway are subject to various important factors that may affect actual results[9] - Completion of quarterly results will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024[3]

Core Viewpoint - Spero Therapeutics is progressing well with its Phase 3 PIVOT-PO trial of tebipenem HBr, expecting to complete enrollment in the second half of 2025, while also managing its financial resources effectively to extend its cash runway into mid-2026 [1][2][10]. Pipeline Update - Tebipenem HBr is an investigational oral carbapenem antibiotic aimed at treating complicated urinary tract infections (cUTI), potentially reducing hospitalizations [3][4]. - The PIVOT-PO trial is a randomized, double-blinded study comparing oral tebipenem HBr with intravenous imipenem cilastatin, targeting approximately 2,648 patients [4]. - SPR206 is another investigational drug showing activity against multi-drug resistant Gram-negative pathogens, with plans for a Phase 2 trial pending funding [5][6]. Financial Results - For Q3 2024, Spero reported a net loss of $17.1 million, or ($0.32) per share, compared to a net loss of $3.2 million, or ($0.06) per share in Q3 2023 [10][18]. - Total revenue for Q3 2024 was $13.5 million, down from $25.5 million in Q3 2023, primarily due to lower collaboration revenues [10][18]. - Research and development expenses increased to $26.9 million in Q3 2024 from $16.4 million in the same period in 2023, attributed to higher clinical trial costs [10][18]. Corporate Update - Following the suspension of the SPR720 development program, Spero underwent a restructuring that included a 39% reduction in workforce, which has extended its cash runway into mid-2026 [9][10].

Financial Position - As of September 30, 2024, the company had an accumulated deficit of $438.8 million and cash and cash equivalents of $76.3 million[158]. - As of September 30, 2024, the company had cash and cash equivalents of $76.3 million, which is expected to fund operating expenses and capital requirements for at least 12 months[192]. - The company anticipates needing additional funding beyond the 12-month period, which may include equity or debt financings, new collaborations, or grant funding[192]. Revenue and Income - The company has not generated any revenue from product sales to date and cannot predict future revenue generation from product commercialization[167]. - Total revenues for the three months ended September 30, 2024, were $13.5 million, a decrease of $12.0 million compared to $25.5 million in the same period of 2023[177]. - Grant revenue for the three months ended September 30, 2024, was $5.7 million, an increase of $3.6 million from $2.1 million in the same period of 2023[177]. - Collaboration revenue from related parties decreased by $15.4 million to $7.8 million in the three months ended September 30, 2024, compared to $23.4 million in 2023[178]. - For the nine months ended September 30, 2024, total revenues were $32.9 million, an increase of $2.7 million from $30.3 million in 2023[181]. - Grant revenue for the nine months ended September 30, 2024, was $14.9 million, an increase of $9.5 million from $5.3 million in 2023[181]. - The company recognized $14.6 million in grant revenue from the BARDA contract for tebipenem HBr during the nine months ended September 30, 2024, an increase of $11.5 million from $3.1 million in 2023[181]. - Collaboration revenue for the nine months ended September 30, 2024, was $18.0 million, a decrease of $6.87 million from $24.9 million in the same period of 2023[182]. - The company recognized $17.7 million in collaboration revenue from GSK and $0.3 million from Pfizer for the nine months ended September 30, 2024[182]. Expenses - The company expects to incur significant expenses and increasing operating losses for at least the next several years[158]. - Research and development expenses primarily consist of costs related to drug discovery and development, with significant external costs tracked on a program-by-program basis[168]. - Research and development expenses increased by $10.5 million to $26.9 million for the three months ended September 30, 2024, compared to $16.4 million in 2023[179]. - Research and development expenses totaled $67.9 million for the nine months ended September 30, 2024, an increase of $33.04 million compared to $34.9 million for the same period in 2023[183]. - Direct costs for the tebipenem HBr program increased by $30.5 million during the nine months ended September 30, 2024, due to ongoing clinical activities[185]. - Total operating expenses for the three months ended September 30, 2024, were $32.1 million, an increase of $4.7 million from $27.4 million in 2023[177]. - General and administrative expenses decreased to $16.6 million for the nine months ended September 30, 2024, down by $2.47 million from $19.1 million in 2023[186]. Losses - The net loss for the three months ended September 30, 2024, was $17.1 million, an increase of $13.9 million from a net loss of $3.2 million in the same period of 2023[177]. - Net cash used in operating activities for the nine months ended September 30, 2024, was less than $0.1 million, compared to $15.5 million for the same period in 2023[188]. Strategic Restructuring - The strategic restructuring announced on October 29, 2024, included a workforce reduction of approximately 39%, with estimated costs of $1.1 million related to severance and termination benefits[160]. - The company anticipates a substantial reduction in future development-related expenses following the suspension of SPR720 and the implementation of its restructuring[173]. - The company plans to make reductions in spending if adequate additional funding is not secured, which may delay or eliminate planned clinical trials and research programs[192]. Clinical Development - The Phase 3 clinical trial for tebipenem HBr is on track, targeting enrollment of approximately 2,648 patients, with completion expected in the second half of 2025[163]. - An additional contract modification of $11.7 million was executed under the existing contract with BARDA, increasing total committed funding to $59.3 million for tebipenem HBr clinical development[164]. - The FDA cleared the investigational new drug application for SPR206, with plans to initiate a Phase 2 trial pending non-dilutive funding availability[165]. Future Outlook - Future cash requirements will depend on clinical trial costs, regulatory approvals, and potential collaborations[191]. - The company has no material changes to its contractual obligations and commitments during the three and nine months ended September 30, 2024[194]. - There are currently no off-balance sheet arrangements affecting the company[195]. - The primary objectives of the company's investment activities are to preserve principal, provide liquidity, and maximize income without significantly increasing risk[195]. - The company faces exposure to foreign currency exchange rate movements, primarily with the Euro, British Pound, Japanese Yen, and Australian Dollar against the U.S. dollar[195]. - Historically, foreign currency fluctuations have not had a material impact on the company's consolidated financial statements[195]. - The company does not have any assets classified as marketable securities as of September 30, 2024[195]. - The company is classified as a smaller reporting company and is not required to provide certain disclosures under SEC rules[195].

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Conference Call August 5, 2024 4:30 AM ET Company Participants Shai Biran - Senior Director Investor Relations Sath Shukla - Chief Executive Officer Esther Rajavelu - CFO and Chief Business Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Gavin Clark-Gartner - Evercore ISI Ritu Baral - TD Cowen Operator Good afternoon and welcome to the Spero Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share SPRO The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update • Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024 • New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in October • Company announces departure of Chief Medical Of icer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committe ...

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline. To acce ...

Exhibit 99.1 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update CAMBRIDGE, Mass., May 15, 2024 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial and operational results for the quarter ended March 31, 2024. "We continued to make progress towards our stated goals ac ...